The industries for medical equipment, drug and biotechnology have long been supporters of efforts to make permanent the research and development tax credit. "We look forward to seeing the details of [the] new proposal and the other tax changes being discussed today to determine how they will affect America's medical technology companies," said Brett Loper, AdvaMed's senior executive vice president for government affairs.

Full Story:
Hill, The

Related Summaries